INDV News & Events

Reports Q4 revenue $358M, consensus $305.62M. "In 2025 we successfully completed Phase I of the Indivior Action Agenda - Generate Momentum," said Joe Ciaffoni, Chief Executive Officer. "We sharpened our focus on our highest growth opportunity, U.S. SUBLOCADE, established our "go-forward" operating model and strengthened our financial profile. We are now executing Phase II of the Indivior Action Agenda - Accelerate, which includes accelerating SUBLOCADE throughout 2026 and immediately accelerating adjusted EBITDA and cash flow at a faster rate. We expect our increased cash flow will enable us to strategically deploy capital to create value for our shareholders."

"We delivered on our financial commitments in 2025, growing total SUBLOCADE net revenue 13% and adjusted EBITDA 20%, while positioning Indivior for acceleration in 2026," said Ryan Preblick, Chief Financial Officer. "In 2026, we expect to deliver SUBLOCADE dispense unit growth in the mid-teens with operating expenses that will not exceed $450 million, and generate approximately $300 million in cash flow from operations. Our capital deployment priorities include managing our debt, opportunistically deploying our new $400 million share repurchase program and evaluating business development opportunities as we earn our way to Phase III of the Indivior Action Agenda - Breakout."

Sees adjusted EBITDA $535M-$575M.

Indivior Pharmaceuticals announced completion of its redomiciliation from the United Kingdom to the United States. As a result, Indivior Pharmaceuticals, a new Delaware corporation, has become the new parent company. Indivior PLC is renamed Indivior and has become a wholly-owned subsidiary of IPI. The common stock of Indivior Pharmaceuticals is listed on Nasdaq and will continue to trade under the symbol "INDV."